Risk factors

Spero Therapeutics (SPRO) risk factors

Item 1A of every Spero Therapeutics, Inc. 10-K on file, and what changed from one year to the next.

Open SPRO in Gloomberb →
  • FY2025 10-K risk factors

    75 risks, 11 new, 17 dropped, 20 reworded since the prior year. Spero Therapeutics faces heightened operational risks regarding clinical trial uncertainties, debt financing needs, and external macroeconomic pressures like new tariffs and tax laws.

    Filed Mar 26, 2026
  • FY2024 10-K risk factors

    81 risks. Spero Therapeutics relies heavily on the success, regulatory approval, and commercialization of its lead product candidate tebipenem HBr under a partnership with GSK.

    Filed Mar 27, 2025